Legal & General Group
ORIC icon

Legal & General Group’s Oric Pharmaceuticals ORIC Stock Holding History

Legal & General Group’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$332K Buy
30,667
+1,331
+5% +$12.1K ﹤0.01% 2483
2026
Q1 		$372K Sell
29,336
-4,503
-13% -$51.1K ﹤0.01% 2438
2025
Q4 		$277K Buy
33,839
+713
+2% +$8.21K ﹤0.01% 2541
2025
Q3 		$398K Buy
33,126
+28,787
+663% +$303K ﹤0.01% 2506
2025
Q2 		$44K Sell
4,339
-28,119
-87% -$189K ﹤0.01% 2737
2025
Q1 		$181K Sell
32,458
-470
-1% -$4.11K ﹤0.01% 2624
2024
Q4 		$266K Hold
32,928
– – ﹤0.01% 2630
2024
Q3 		$338K Buy
32,928
+409
+1% +$4.04K ﹤0.01% 2580
2024
Q2 		$230K Buy
32,519
+29,266
+900% +$262K ﹤0.01% 2649
2024
Q1 		$44.7K Hold
3,253
– – ﹤0.01% 2791
2023
Q4 		$29.9K Hold
3,253
– – ﹤0.01% 2896
2023
Q3 		$19.7K Sell
3,253
-501
-13% -$4.11K ﹤0.01% 3039
2023
Q2 		$29.1K Buy
+3,754
New +$21.3K ﹤0.01% 2968
2022
Q3 		– Sell
-2,530
Closed -$11K – 3475
2022
Q2 		$11K Sell
2,530
-7,076
-74% -$28.2K ﹤0.01% 3365
2022
Q1 		$51K Hold
9,606
– – ﹤0.01% 2999
2021
Q4 		$142K Buy
9,606
+560
+6% +$8.73K ﹤0.01% 2829
2021
Q3 		$189K Buy
9,046
+4,889
+118% +$99.1K ﹤0.01% 2712
2021
Q2 		$74K Sell
4,157
-345
-8% -$7.56K ﹤0.01% 2826
2021
Q1 		$110K Buy
4,502
+1,260
+39% +$39.8K ﹤0.01% 2592
2020
Q4 		$110K Buy
3,242
+2,170
+202% +$62.3K ﹤0.01% 2562
2020
Q3 		$27K Sell
1,072
-340
-24% -$8.09K ﹤0.01% 2882
2020
Q2 		$47K Buy
+1,412
New +$45.1K ﹤0.01% 2747

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Legal & General Group's ORIC Position: Q2 2026 in Review

Legal & General Group increased its Oric Pharmaceuticals (ORIC) stake by 4.5% in Q2 2026, buying an estimated $12.1K and bringing the position to 30,667 shares worth $332K. The position accounts for ﹤0.01% of the portfolio, ranked #2483.

Legal & General Group first reported a position in ORIC in Q2 2020 and has held it in 22 quarters since. The position peaked at $398K in Q3 2025. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Legal & General Group held 30,667 shares of Oric Pharmaceuticals worth $332K as of Q2 2026.
  • Legal & General Group bought 1,331 Oric Pharmaceuticals shares in Q2 2026, an estimated $12.1K.
  • Oric Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2483 holding.
  • Legal & General Group first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 22 quarters since.
  • Legal & General Group's Oric Pharmaceuticals position peaked at $398K in Q3 2025.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.